Skip to content

the efficacy of 3 regimens of misoprostol in second trimester pregnancy termination

comparison the efficacy of 3 regimens (vaginal, sublingual and combined) of misoprostol in 13-24 weeks of gestation pregnancy termination and their complication

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201012235452N1
Enrollment
195
Registered
2012-03-15
Start date
2012-02-04
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

medical abortion. termination of pregnancy: · legal · therapeutic therapeutic abortion

Interventions

Intervention 1: Misoprostol, 400 microgram, vaginal, every 4 hours, within 48 hours. Intervention 2: Misoprostol, 400 microgram, sublingual , every 4 hours, within 48 hours. Intervention 3: Misoprosto
Treatment - Drugs
Misoprostol, 400 microgram, vaginal, every 4 hours, within 48 hours
Misoprostol, 400 microgram, sublingual , every 4 hours, within 48 hours
Misoprostol, 400 microgram, vaginal, then 400 microgram sublingual every 4 hours, within 48 hours

Sponsors

Vice chancellor for research of school of medicine , Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: inclusion criteria: any pregnant women with gestational age of 13-24 weeks which has indication for medical pregnancy termination including fetal or maternal indication. exclusion criteria : any hypersensitivity to prostaglandins; pregnant women who are high risk for uterine rupture(having more than one history of histrotomy or section, having history of uterine classic or Tshape incision, having extensive surgery on the uterine fundos, multi-parity more than 5); pregnant women with IUD;pregnant women having medical conditions such as severe anemia, anticoagulation state, taking anticoagulative drugs, active liver disease, and cardiovascular disease; pregnant women having glaucoma; pregnant women having uncontrolled seizure; pregnant women having adrenal disease or taking corticosteroids such as in bronchial asthma

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Abortion rate in 24 and 48 hour after starting misoprostol usage. Timepoint: after 24 and 48 hour. Method of measurement: physical exam and transvaginal sonography.;Side effect of misoprostol in each group. Timepoint: each hour. Method of measurement: observation and asking the patient.

Secondary

MeasureTime frame
Residual of all or a part of placenta which need a surgical procedure. Timepoint: 24- 48 hour later. Method of measurement: vaginal sonography.;The duration from starting misoprostol to successful abortion. Timepoint: each hour. Method of measurement: observation, counting time.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Fatemeh Rahimi Sherbaf

Tehran University of Medical Sciences

rahimish@sina.tums.ac.ir+98 21 8890 0002

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026